Form 4: Enliven Therapeutics CFO Benjamin Hohl Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Enliven Therapeutics' CFO, Benjamin Hohl, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Benjamin Hohl, CFO of Enliven Therapeutics, reported exercising stock options to acquire common stock.
- He also sold a portion of the acquired shares.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
- On December 13, 2024, Hohl exercised options for 13,000 shares at a price of $2.48 per share.
- On January 3, 2025, he exercised options for 1,000 shares at $2.48 per share and sold 1,000 shares at a weighted average price of $25.0386.
- Following these transactions, Hohl directly owns 13,000 shares of common stock and holds options for 150,306 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects. The sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The filing itself doesn't provide specific insights into the company's performance or future prospects, but it does show that the CFO is exercising and selling shares.
Stakeholder Impact
- Shareholders may be interested in insider trading activity as it can provide insights into management's view of the company's stock.
Key Dates
| Date | Description |
|---|---|
| June 26, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| August 2, 2022 | Date one-fourth of the original stock option vested. |
| December 13, 2024 | Date of stock option exercise for 13,000 shares. |
| December 27, 2024 | Date of subsequent option exercises as reported in a Form 4 filed on December 31, 2024. |
| December 30, 2024 | Date of subsequent option exercises as reported in a Form 4 filed on December 31, 2024. |
| January 3, 2025 | Date of stock option exercise and sale of shares. |
| January 7, 2025 | Date of Form 4 filing. |
| August 2, 2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.